Annals of Hepatology

VIRAL HEPATITIS

| VIIVAL TILI ATTTIS |
|--|
| Effects on anemia of drug adjustment in patients with chronic hepatitis C during telaprevir-combined therapy |
| Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C |
| Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis |
| Mycobacterium abscessus pulmonary infection during hepatitis C treatment with telaprevir, peginterferon and ribavirin |
| Acute hepatitis E virus infection and association with a subacute thyroiditis |
| Pathophysiological and pharmacological implications of elucidating the molecular bases of the interaction between HBV and the bile acid transporter NTCP |
| The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis |
| Prospective study of hepatitis B virus reactivation in patients with hematological malignancies |
| LAM add-on ADV combination therapy or ETV monotherapy for CHB patients with suboptimal response to ADV |
| Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis |
| The fatigue impact scale for daily use in patients with hepatitis B virus and hepatitis C virus chronic infections |
| Does hepatitis B virus coinfection have any impact on treatment outcome in hepatitis C patients on hemodialysis? |
| HCV antiviral therapy in injection drug users: difficult to treat or easy to cure? |
| Inter and intrapatient evolution of hepatitis C virus 14:442-cre |
| The function of MicroRNA in hepatitis B virus-related liver diseases: from Dim to Bright |
| Hypovitaminosis D and its relation to demographic and laboratory data among hepatitis C patients |
| Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients 14:464-oa |
| Detection of hepatitis B activity in HBeAg-negative carriers with normal aminotransferase levels in central Brazil |

SUBJECT INDEX VOLUME 14, 2015

| High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain |
|---|
| Liver-specific case fatality due to chronic hepatitis C virus infection: a systematic review 14:618-cre |
| Increase of drug use and genotype 3 in HCV-infected patients from Central West and Northeast Mexico |
| Intermediate fibrosis staging in hepatitis C: a problem not overcome by optimal samples or pathologists' expertise |
| Cholestatic hepatitis C after chemotherapy containing rituximab in diffuse large B cell lymphoma 14:756-cr |
| Meeting the Eastern perspective in hepatitis B related ACLF |
| Prevalence of hepatitis C virus infection among patients undergoing haemodialysis in Latin America 14:807-cre |
| Prevalence of hepatitis B and C markers in a population of an urban university in Rio de Janeiro, Brazil: a cross-sectional study |
| Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B |
| HEDATOCELLIII AD CARCINOMA |
| HEPATOCELLULAR CARCINOMA |
| Factors associated with recurrence and survival in liver transplant patients with HCC - a single center retrospective study |
| Factors associated with recurrence and survival in liver transplant patients with |
| Factors associated with recurrence and survival in liver transplant patients with HCC - a single center retrospective study |
| Factors associated with recurrence and survival in liver transplant patients with HCC - a single center retrospective study |
| Factors associated with recurrence and survival in liver transplant patients with HCC - a single center retrospective study |
| Factors associated with recurrence and survival in liver transplant patients with HCC - a single center retrospective study |
| Factors associated with recurrence and survival in liver transplant patients with HCC - a single center retrospective study |
| Factors associated with recurrence and survival in liver transplant patients with HCC - a single center retrospective study |
| Factors associated with recurrence and survival in liver transplant patients with HCC - a single center retrospective study |

| A simple diagnostic index comprising epithelial | Involvement of the receptor for |
|---|--|
| membrane antigen and fibronectin for | advanced glycation end products in liver transplantation 14:190-oa |
| hepatocellular carcinoma | |
| | Liver allografts from donors with peritoneal |
| Evaluation of alpha-fetoprotein as a | contamination: report of two cases |
| screening marker for hepatocellular carcinoma in | |
| hepatitis prevalent areas | Risk factors for early repeat ERCP in |
| | liver transplantation patients with anastomotic |
| | biliary stricture 14:340-oa |
| LIVER CIRRHOSIS AND ITS' | |
| | Comorbidities have a limited impact on |
| COMPLICATION | post-transplant survival in carefully selected |
| | cirrhotic patients: a population-based cohort study 14:505-oa |
| Portal vein thrombosis: What is new? 14:20-cre | |
| | Transient hyperglycemia during liver transplantation |
| The performance of prognostic models as | does not affect the early graft function 14:675-oa |
| predictors of mortality in patients with | |
| acute decompensation of cirrhosis | Risk factors for acute kidney injury and |
| | 30-day mortality after liver transplantation 14:688-oa |
| Thrombosis and hemorrhage in the | |
| critically ill cirrhotic patients: | Secondary sclerosing cholangitis following major burn 14:695-oa |
| five years retrospective prevalence study | |
| | Predicting early discharge from |
| Factors associated with 25-hydroxyvitamin D | hospital after liver transplantation (ERDALT) |
| levels in patients with liver cirrhosis | at a single center: a new model |
| | |
| Paradoxical embolization in TIPS: | Assessing risk factors of acute kidney |
| take a closer look to the heart | injury after liver transplantation |
| | |
| Enterococcus casseliflavus and | Acute kidney injury after liver transplantation is |
| Enterococcus gallinarum as causative agents of | associated with viral hepatitis, prolonged warm ischemia, |
| spontaneous bacterial peritonitis | lactate and higher mortality |
| | - · |
| Clinical characteristics, predictors, and survival | |
| among patients with hepatopulmonary syndrome 14:354-oa | |
| among patients with nepatopatinolary syndrome 11.55 Fou | MISCELLANEOUS |
| anong patients marriepatopatinonary syndrome | MISCELLANEOUS |
| Exercise capacity of cirrhotic patients with | |
| | Identification of cholesterol gallstone |
| Exercise capacity of cirrhotic patients with | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |
| Exercise capacity of cirrhotic patients with hepatopulmonary syndrome | Identification of cholesterol gallstone with two-dimensional gel electrophoresis and mass spectrometry |

| Association of a morel TACORON banks to many the | Development of startal analysis in |
|---|---|
| Association of a novel TAS2R38 haplotype with alcohol intake among Mexican-Mestizo population 14:729-oa | Development of steatohepatitis in Ob/Ob mice is dependent on Toll-like receptor 4 |
| Swallowed chicken bone migration into the liver 14:744-ih | Correlation between serum cytokeratin-18 and the progression or regression of |
| Pearls for optimizing biomedical manuscripts 14:774-ed | non-alcoholic fatty liver disease |
| Drug-induced fatty liver disease: An overview of pathogenesis and management | Isolated liver disease in a patient with a CFTR genotype F508del/12TG-5T and 470MV: A new face of an old disease |
| Drug-induced liver injury in | |
| hospitalized HIV patients: high incidence and association with drugs for tuberculosis | Nonalcoholic fatty liver disease and polycystic ovary syndrome |
| Contrast-induced acute kidney injury in | |
| cirrhotic patients. A retrospective analysis | LIVER FAILURE |
| The limited prognostic value of | Traditional Chinese Medicine and |
| liver histology in children with biliary atresia 14:902-oa | herbal hepatotoxicity: |
| Maternal separation on the | a tabular compilation of reported cases14:7-cre |
| ethanol-preferring adult rat liver structure | Usefulness of serum thursis stimulation bermana (TSU) |
| | Usefulness of serum thyroid-stimulation hormone (TSH) as a prognostic indicator for |
| Isolated liver disease in a patient with a CFTR genotype F508del/12TG-5T and 470MV: | acute-on-chronic liver failure |
| A new face of an old disease | |
| Anew face of all old disease | Liver-specific case fatality due to chronic hepatitis C virus infection: a systematic review 14:618-cre |
| NON ALCOHOLIC | Granulocyte-colony stimulating factor for |
| FATTY LIVER DISEASE (NAFLD) | acute-on-chronic liver failure: systematic review and meta-analysis |
| Effects of a law fot dist on the | systematic review and meta analysis |
| Effects of a low-fat diet on the hepatic expression of adiponectin and its | Etiology, outcome and prognostic factors of |
| receptors in rats with NAFLD | childhood acute liver failure in a German Single Center 14:722-oa |
| | Gastrointestinal neuroendocrine tumor with |
| Lifestyle changes associated with a new antioxidant formulation in non-alcoholic fatty | unresectable liver metastases: |
| liver disease: a case series | an example of multimodal therapeutic approach 14:752-cr |
| | |
| Granulocyte-colony stimulating factor | VASCULAR DISORDERS |
| prevents the development of hepatic steatosis in rats 14:243-oa | VASCOLAR DISORDERS |
| The role of small heterodimer partner in | Intrahepatic aneurysmal portohepatic venous shunt: |
| hepatic lipid homeostasis | what should be done? |
| Impact of H63D mutations, magnetic resonance and | Congenital double intrahepatic portosystemic shunt: |
| metabolic syndrome among outpatient referrals for | Imaging findings and endovascular closure |
| elevated serum ferritin in the Basque Country | |
| | |
| Obsticholic acid: expanding the | HERATORII IARV. MALICAIANGIEG |
| Obeticholic acid: expanding the therapeutic landscape of NASH | HEPATOBILIARY MALIGNANCIES |
| therapeutic landscape of NASH | The White-test helps to reduce biliary leakage in |
| therapeutic landscape of NASH | |
| therapeutic landscape of NASH | The White-test helps to reduce biliary leakage in liver resection: a systematic review and meta-analysis 14:161-cre |
| therapeutic landscape of NASH | The White-test helps to reduce biliary leakage in liver resection: a systematic review and meta-analysis 14:161-cre Papillary in situ and intramucosal adenocarcinoma of the lower third of common bile duct. |
| therapeutic landscape of NASH | The White-test helps to reduce biliary leakage in liver resection: a systematic review and meta-analysis 14:161-cre Papillary in situ and intramucosal adenocarcinoma of |
| therapeutic landscape of NASH | The White-test helps to reduce biliary leakage in liver resection: a systematic review and meta-analysis 14:161-cre Papillary in situ and intramucosal adenocarcinoma of the lower third of common bile duct. A report and review of the literature |
| therapeutic landscape of NASH | The White-test helps to reduce biliary leakage in liver resection: a systematic review and meta-analysis 14:161-cre Papillary in situ and intramucosal adenocarcinoma of the lower third of common bile duct. A report and review of the literature |
| therapeutic landscape of NASH | The White-test helps to reduce biliary leakage in liver resection: a systematic review and meta-analysis 14:161-cre Papillary in situ and intramucosal adenocarcinoma of the lower third of common bile duct. A report and review of the literature |
| therapeutic landscape of NASH | The White-test helps to reduce biliary leakage in liver resection: a systematic review and meta-analysis 14:161-cre Papillary in situ and intramucosal adenocarcinoma of the lower third of common bile duct. A report and review of the literature 14:425-cr Management of liver metastases of gastrointestinal stromal tumors (GIST) 14:531-oa |
| therapeutic landscape of NASH | The White-test helps to reduce biliary leakage in liver resection: a systematic review and meta-analysis 14:161-cre Papillary in situ and intramucosal adenocarcinoma of the lower third of common bile duct. A report and review of the literature |
| therapeutic landscape of NASH | The White-test helps to reduce biliary leakage in liver resection: a systematic review and meta-analysis 14:161-cre Papillary in situ and intramucosal adenocarcinoma of the lower third of common bile duct. A report and review of the literature 14:425-cr Management of liver metastases of gastrointestinal stromal tumors (GIST) 14:531-oa |
| therapeutic landscape of NASH | The White-test helps to reduce biliary leakage in liver resection: a systematic review and meta-analysis 14:161-cre Papillary in situ and intramucosal adenocarcinoma of the lower third of common bile duct. A report and review of the literature |
| therapeutic landscape of NASH | The White-test helps to reduce biliary leakage in liver resection: a systematic review and meta-analysis 14:161-cre Papillary in situ and intramucosal adenocarcinoma of the lower third of common bile duct. A report and review of the literature |
| therapeutic landscape of NASH | The White-test helps to reduce biliary leakage in liver resection: a systematic review and meta-analysis 14:161-cre Papillary in situ and intramucosal adenocarcinoma of the lower third of common bile duct. A report and review of the literature |

| Cutaneous amyloidosis associated with | HEPATITIS |
|--|--|
| autoimmune hepatitis-primary biliary cirrhosis overlap syndrome | Fibro-check: a combination of direct and indirect markers for liver fibrosis staging in |
| Successful pregnancy after ileal exclusion in | chronic hepatitis C patients |
| progressive familial intrahepatic cholestasis type 2 14:550-cr | Reasons for HCV non-treatment in |
| Colorectal cancer surveillance in primary sclerosing cholangitis and | underserved African Americans: Implications for treatment with new therapeutics |
| inflammatory bowel disease | IFNL3 polymorphisms and HCV infection in |
| Reversal of advanced fibrosis after long-term | patients with beta thalassemia |
| ursodeoxycholic acid therapy in a patient with residual expression of MDR3 | Mycophenolic acid induces apoptosis of hepatic stellate cells in an <i>in vitro</i> model of HCV 14:396-oa |
| Severe hypercholesterolemia mediated by lipoprotein X in a patient with cholestasis | Black hairy tongue during interferon therapy for hepatitis C |
| LIVER FIBROSIS | LIVER HEPATITIS |
| Prevalence in vulnerable population of liver fibrosis identified by transient elastography | Telaprevir may induce adverse cutaneous reactions by a T cell immune-mediated mechanism 14:420-cr |